BRAINSTORM CELL THERAPEUTICS INC.
For the period ended Mar 31, 2025. Filed May 15, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2025 · Filed May 15, 2025
BCLI$0.97+1.0%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Interim Condensed Statements of Changes in Stockholders’ Equity (Deficit
STATEMENTS OF CHANGES IN STOCKHOLDERS’ EQUITY**(UNAUDITED)**
| | | | | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | | | | | Additional | | | | | | Total |
| · · Common stock · · paid-in · · Treasury · · Accumulated · · stockholders’ | ||||||||||||
| · Number (**) · Amount · capital · stocks · deficit · deficit | ||||||||||||
| Balance as of January 1, 2024 | 4,032,614 | | 13 | | 210,258 | | (116) | | (215,013) | | (4,858) | |
| Stock-based compensation related to stock and options granted to directors and employees | | — | | * | | 170 | | — | | — | | 170 |
| Issuance of shares in at-the-market (ATM) offering (Note 5) | | 530,532 | | * | | 2,539 | | — | | — | | 2,539 |
| Net loss | | — | | — | | — | | — | | (3,401) | | (3,401) |
| Balance as of March 31, 2024 | | 4,563,146 | | 13 | | 212,967 | | (116) | | (218,414) | | (5,550) |
- Represents an amount less than $1.
**Retroactively adjusted (See Note 5).
STATEMENTS OF CHANGES IN STOCKHOLDERS’ EQUITY (DEFICIT) (UNAUDITED)
| | | | | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | | | | | Additional | | | | | | Total |
| · · Common stock · · paid-in · · Treasury · · Accumulated · · stockholders’ | ||||||||||||
| · Number · Amount · capital · stocks · deficit · deficit | ||||||||||||
| Balance as of January 1, 2025 | 6,141,762 | | 14 | | 218,974 | | (116) | | (226,636) | | (7,764) | |
| Stock-based compensation related to stock and options granted to directors and employees | — | | * | | 717 | | — | | — | | 717 | |
| Issuance of shares in at-the-market (ATM) offering (Note 5) | | 388,059 | | * | | 685 | | — | | — | | 685 |
| Exercise of warrants (Note 5) | | 1,381,383 | | 1 | | 1,768 | | — | | — | | 1,769 |
| Net loss | | — | | — | | — | | — | | (2,864) | | (2,864) |
| Balance as of March 31, 2025 | | 7,911,204 | | 15 | | 222,144 | | (116) | | (229,500) | | (7,457) |
- Represents an amount less than $1.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.